Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies

Page 8 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaCompletedNCT00077922Phase 2Results posted
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
• Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLLCompletedNCT00074282Phase 2Results posted
• Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
• Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersCompletedNCT00071396Phase 2Results posted
• Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LeukemiaCompletedNCT00060424Phase 2Results posted
• Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00058240Phase 1/2Results posted
• Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or LymphomaCompletedNCT00057811Phase 2Results posted
• Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
• Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
• Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00014560Phase 1Results posted
• Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/2Results posted
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaCompletedNCT00003659Phase 2Results posted
• Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisCompletedNCT00001586Phase 2Results posted
• Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaActive, not recruitingNCT07166419Phase 1
• Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersActive, not recruitingNCT07162181Phase 2
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Phase 3
• A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT06839872Phase 2
• Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy VolunteersCompletedNCT06787131Phase 1
• Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid BiopsyCompletedNCT06782854
• A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)TerminatedNCT06761586Phase 1
• Epcoritamab in Chronic Lymphocytic Leukemia and Richter SyndromeActive, not recruitingNCT06676033Phase 1
• A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT06637501Phase 2
• 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
• A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLActive, not recruitingNCT06547528Phase 1
• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodActive, not recruitingNCT06524375Phase 2
• Exercise As Intervention in Chronic Lymphocytic LeukemiaActive, not recruitingNCT06396611Not applicable
• A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanCompletedNCT06362044
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic MalignanciesTerminatedNCT06343376Phase 1
• A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT06291220Phase 1
• AGMT Austrian CLL (Chronic Lymphocytic Leukemia) RegistryCompletedNCT06250465
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
• Acalabrutinib Real World Italian obSErvational Study -ARISEActive, not recruitingNCT06205498
• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnNCT06205290Phase 3
• REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaActive, not recruitingNCT06170671
• A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainActive, not recruitingNCT06125795
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT06073821Phase 3
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
• Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingNCT05971251Phase 1
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05963074Phase 2
• A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesActive, not recruitingNCT05944978Phase 1/2
• Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCTCompletedNCT05928156Not applicable
• HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT05879133Not applicable
• Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Active, not recruitingNCT05878184Phase 1
• Biomarker for Infection Risk in CLL and MMActive, not recruitingNCT05844033
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesTerminatedNCT05828589Phase 1
• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesActive, not recruitingNCT05797233Phase 1
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruitingNCT05753501Phase 1
• A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaTerminatedNCT05720052Phase 1/2
• Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyActive, not recruitingNCT05718869Phase 2
• A Case Crossover Study of Intermittent Fasting in CLL/SLLCompletedNCT05708326Not applicable
• Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesCompletedNCT05694364Phase 1
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05677919Phase 2
• A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic LeukemiaCompletedNCT05672355Phase 2
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
• Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabActive, not recruitingNCT05650723Phase 2
• Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.TerminatedNCT05645744
• A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)Active, not recruitingNCT05624554Phase 3
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsActive, not recruitingNCT05618028Phase 1
• CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/LymphomaWithdrawnNCT05613348Phase 1/2
• Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic MalignanciesWithdrawnNCT05570188Phase 1/2
• Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialActive, not recruitingNCT05556720Phase 3
• A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United KingdomCompletedNCT05555979
• Cardiotoxicities in Patients Receiving BTKiWithdrawnNCT05521178
• A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLTerminatedNCT05515406Phase 1
• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05512390Phase 1
• Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Phase 2
• Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLLActive, not recruitingNCT05478512Phase 2
• Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLLWithdrawnNCT05465876Phase 2
• A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Active, not recruitingNCT05458297Phase 2
• National Acalabrutinib Observational StudyActive, not recruitingNCT05437250
• A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05424822Phase 1
• Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell MalignanciesWithdrawnNCT05410041Phase 1
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
• Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxTerminatedNCT05317936Phase 1/2
• Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic LeukemiaCompletedNCT05316831Phase 4
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLLTerminatedNCT05272813Phase 1/2
• MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
• Phase I Study of JWCAR029 in Subjects With R/R CLL/SLLWithdrawnNCT05259813Phase 1
• A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT05244070Phase 1
• Financial Difficulty in Patients With Blood CancerCompletedNCT05212233
• Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
• Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyStatus unknownNCT05154474
• Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
• Pneumococcal Vaccination in Patients With Chronic Lymphocytic LeukaemiaStatus unknownNCT05145101
• Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
• CLL Therapy Approaches in RussiaActive, not recruitingNCT05140369
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
• Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh NationalityCompletedNCT05095155
• CAR20.19.22 T-cells in Relapsed, Refractory B-cell MalignanciesTerminatedNCT05094206Phase 1

← Leukemia, Lymphocytic, Chronic, B-Cell overview